Joshua A Beckman1, Meredith S Duncan2, Charles W Alcorn3, Kaku So-Armah4, Adeel A Butt5,6, Matthew Bidwell Goetz7, Hilary A Tindle8,9, Jason J Sico10, Russel P Tracy11, Amy C Justice10,12, Matthew S Freiberg2,9. 1. Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (J.A.B., M.S.D., M.S.F.). Joshua.a.beckman@vanderbilt.edu. 2. Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (J.A.B., M.S.D., M.S.F.). 3. Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, PA (C.W.A.). 4. Section of General Internal Medicine, Boston University School of Medicine, MA (K.S.-A.). 5. Department of Medicine, Weill Cornell Medical College, New York, NY (A.A.B.). 6. Veterans Association Pittsburgh Healthcare System, PA (A.A.B.). 7. Department of Medicine, VA Greater Los Angeles Healthcare System and David Geffen School of Medicine, University of California (M.B.G.). 8. Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.A.T.). 9. Geriatric Research Education and Clinical Centers, Veterans Affairs Tennessee Valley Healthcare System, Nashville (H.A.T., M.S.F.). 10. Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center (J.J.S, A.C.J.). 11. Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington (R.P.T.). 12. Yale University Schools of Medicine and Public Health, New Haven, CT (A.C.J.).
Abstract
BACKGROUND: The effect of human immunodeficiency virus (HIV) on the development of peripheral artery disease (PAD) remains unclear. We investigated whether HIV infection is associated with an increased risk of PAD after adjustment for traditional atherosclerotic risk factors in a large cohort of HIV-infected (HIV+) and demographically similar HIV-uninfected veterans. METHODS: We studied participants in the Veterans Aging Cohort Study from April 1, 2003 through December 31, 2014. We excluded participants with known prior PAD or prevalent cardiovascular disease (myocardial infarction, stroke, coronary heart disease, and congestive heart failure) and analyzed the effect of HIV status on the risk of incident PAD events after adjusting for demographics, PAD risk factors, substance use, CD4 cell count, HIV-1 ribonucleic acid, and antiretroviral therapy. The primary outcome is incident peripheral artery disease events. Secondary outcomes include mortality and amputation in subjects with incident PAD events by HIV infection status, viral load, and CD4 count. RESULTS: Among 91 953 participants, over a median follow up of 9.0 years, there were 7708 incident PAD events. Rates of incident PAD events per 1000 person-years were higher among HIV+ (11.9; 95% confidence interval [CI], 11.5-12.4) than uninfected veterans (9.9; 95% CI, 9.6-10.1). After adjustment for demographics, PAD risk factors, and other covariates, HIV+ veterans had an increased risk of incident PAD events compared with uninfected veterans (hazard ratio [HR], 1.19; 95% CI, 1.13-1.25). This risk was highest among those with time-updated HIV viral load >500 copies/mL (HR, 1.51; 95% CI, 1.38-1.65) and CD4 cell counts <200 cells/mm3 (HR, 1.91; 95% CI, 1.71-2.13). In contrast, HIV+ veterans with time updated CD4 cell count ≥500 cells/mm3 had no increased risk of PAD (HR, 1.03; 95% CI, 0.96-1.11). Mortality rates after incident PAD events are high regardless of HIV status. HIV infection did not affect rates of amputation after incident PAD events. CONCLUSIONS: Infection with HIV is associated with a 19% increased risk of PAD beyond that explained by traditional atherosclerotic risk factors. However, for those with sustained CD4 cell counts <200 cells/mm3, the risk of incident PAD events is nearly 2-fold higher whereas for those with sustained CD4 cell counts ≥500 cells/mm3 there is no excess risk of incident PAD events compared with uninfected people.
BACKGROUND: The effect of human immunodeficiency virus (HIV) on the development of peripheral artery disease (PAD) remains unclear. We investigated whether HIV infection is associated with an increased risk of PAD after adjustment for traditional atherosclerotic risk factors in a large cohort of HIV-infected (HIV+) and demographically similar HIV-uninfected veterans. METHODS: We studied participants in the Veterans Aging Cohort Study from April 1, 2003 through December 31, 2014. We excluded participants with known prior PAD or prevalent cardiovascular disease (myocardial infarction, stroke, coronary heart disease, and congestive heart failure) and analyzed the effect of HIV status on the risk of incident PAD events after adjusting for demographics, PAD risk factors, substance use, CD4 cell count, HIV-1 ribonucleic acid, and antiretroviral therapy. The primary outcome is incident peripheral artery disease events. Secondary outcomes include mortality and amputation in subjects with incident PAD events by HIV infection status, viral load, and CD4 count. RESULTS: Among 91 953 participants, over a median follow up of 9.0 years, there were 7708 incident PAD events. Rates of incident PAD events per 1000 person-years were higher among HIV+ (11.9; 95% confidence interval [CI], 11.5-12.4) than uninfected veterans (9.9; 95% CI, 9.6-10.1). After adjustment for demographics, PAD risk factors, and other covariates, HIV+ veterans had an increased risk of incident PAD events compared with uninfected veterans (hazard ratio [HR], 1.19; 95% CI, 1.13-1.25). This risk was highest among those with time-updated HIV viral load >500 copies/mL (HR, 1.51; 95% CI, 1.38-1.65) and CD4 cell counts <200 cells/mm3 (HR, 1.91; 95% CI, 1.71-2.13). In contrast, HIV+ veterans with time updated CD4 cell count ≥500 cells/mm3 had no increased risk of PAD (HR, 1.03; 95% CI, 0.96-1.11). Mortality rates after incident PAD events are high regardless of HIV status. HIV infection did not affect rates of amputation after incident PAD events. CONCLUSIONS: Infection with HIV is associated with a 19% increased risk of PAD beyond that explained by traditional atherosclerotic risk factors. However, for those with sustained CD4 cell counts <200 cells/mm3, the risk of incident PAD events is nearly 2-fold higher whereas for those with sustained CD4 cell counts ≥500 cells/mm3 there is no excess risk of incident PAD events compared with uninfected people.
Authors: Martin Krsak; David M Kent; Norma Terrin; Christina Holcroft; Sally C Skinner; Christine Wanke Journal: AIDS Patient Care STDS Date: 2015-04-09 Impact factor: 5.078
Authors: Sue Duval; Kirsten Hall Long; Samit S Roy; Niki C Oldenburg; Kelsey Harr; Rebecca M Fee; Ratnendra R Sharma; Nina L Alesci; Alan T Hirsch Journal: J Am Coll Cardiol Date: 2015-10-06 Impact factor: 24.094
Authors: Benjamin M Scirica; Marc P Bonaca; Eugene Braunwald; Gaetano M De Ferrari; Daniel Isaza; Basil S Lewis; Felix Mehrhof; Piera A Merlini; Sabina A Murphy; Marc S Sabatine; Michal Tendera; Frans Van de Werf; Robert Wilcox; David A Morrow Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Marc P Bonaca; Deepak L Bhatt; Robert F Storey; Ph Gabriel Steg; Marc Cohen; Julia Kuder; Erica Goodrich; José C Nicolau; Alexander Parkhomenko; José López-Sendón; Mikael Dellborg; Anthony Dalby; Jindřich Špinar; Philip Aylward; Ramón Corbalán; Maria Teresa B Abola; Eva C Jensen; Peter Held; Eugene Braunwald; Marc S Sabatine Journal: J Am Coll Cardiol Date: 2016-04-01 Impact factor: 24.094
Authors: Aysel Gueler; André Moser; Alexandra Calmy; Huldrych F Günthard; Enos Bernasconi; Hansjakob Furrer; Christoph A Fux; Manuel Battegay; Matthias Cavassini; Pietro Vernazza; Marcel Zwahlen; Matthias Egger Journal: AIDS Date: 2017-01-28 Impact factor: 4.177
Authors: Jin Fan; Adelaide M Arruda-Olson; Cynthia L Leibson; Carin Smith; Guanghui Liu; Kent R Bailey; Iftikhar J Kullo Journal: J Am Med Inform Assoc Date: 2013-10-28 Impact factor: 4.497
Authors: Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling Journal: Clin Infect Dis Date: 2020-03-17 Impact factor: 9.079
Authors: Joshua A Beckman; Meredith S Duncan; Scott M Damrauer; Quinn S Wells; Joey V Barnett; David H Wasserman; Roger J Bedimo; Adeel A Butt; Vincent C Marconi; Jason J Sico; Hilary A Tindle; Marc P Bonaca; Aaron W Aday; Matthew S Freiberg Journal: Circulation Date: 2019-07-08 Impact factor: 29.690
Authors: Sarvesh Chelvanambi; Samir K Gupta; Xingjuan Chen; Bradley W Ellis; Bernhard F Maier; Tyler M Colbert; Jithin Kuriakose; Pinar Zorlutuna; Paul Jolicoeur; Alexander G Obukhov; Matthias Clauss Journal: Circ Res Date: 2019-08-27 Impact factor: 17.367
Authors: Alexandra E Teng; Kevin F Kennedy; Rushi V Parikh; Ehrin J Armstrong; Priscilla Y Hsue; Eric A Secemsky Journal: AIDS Date: 2022-07-15 Impact factor: 4.632
Authors: Allison R Webel; Julie Schexnayder; Patricia A Cioe; Julie A Zuñiga Journal: J Assoc Nurses AIDS Care Date: 2021 May-Jun 01 Impact factor: 1.809
Authors: Natalie E Chichetto; Suman Kundu; Matthew S Freiberg; John R Koethe; Adeel A Butt; Stephen Crystal; Kaku A So-Armah; Robert L Cook; R Scott Braithwaite; Amy C Justice; David A Fiellin; Maria Khan; Kendall J Bryant; Julie R Gaither; Shirish S Barve; Kristina Crothers; Roger J Bedimo; Alberta Warner; Hilary A Tindle Journal: AIDS Behav Date: 2021-06-08